Downstream processing.................... 114, 219, 221, 222,
227, 228, 233–239
Dry powder .......................................................... 489–497
E
Electroporation ............................... 67, 70, 71, 208, 209,
406, 407, 412, 414, 415, 440, 448
Elementary bodies (EBs) ..........................................19–27
ELISpot ......................................410, 411, 415, 419, 420
Encapsulation ..................5, 78, 440, 478, 484, 486, 507
Enzymatic synthesis ............................................. 313–328
Enzyme-linked immunosorbent assay
(ELISA)..........................77, 87, 89, 90, 132, 223,
242, 345, 399, 402, 409, 414–416, 428, 470,
471, 485, 486, 525, 526, 537–546
Enzyme-linked immunosorbent spot
(ELISpot).................................................. 525–535
Escherichia coli (E.coli) ......................................47, 53, 83,
106, 107, 186, 193, 194, 206, 208, 209, 268,
337, 346, 394, 425, 429, 462, 466, 467, 473,
474, 479, 480, 486
Eukaryotic expression vector........................................ 183
Eukaryotic pathogens ...............................................29–41
F
Flavivirus..............................................183, 184, 405–421
Flow cytometry ....................................16, 229, 230, 236,
237, 376, 382, 398, 515, 518–520, 523, 550,
551, 558, 561, 563, 565, 570
G
Gene delivery................................................................. 357
Gene inactivation .......................................................... 331
Gene therapy .............................................. 217, 367–371,
382, 526
Gene vector ................................................................... 357
Glycoconjugates .................................................. 2, 3, 6, 7,
205–214, 267, 287, 290–300, 307–309, 311,
314, 315
Glycoconjugate vaccines ............................ 267, 305–311,
313–328
Glycoconjugation .......................................................... 478
H
Hepatitis B virus (HBV) .................................. 83–93, 437
High performance liquid chromatography
(HPLC)...................................274, 291–296, 302,
316–318, 321, 325, 327
High-throughput process development (HTPD)119–133
Human mesenchymal stem cell
(hMSC) ..................................................... 380–382
Humoral responses .............................514, 538, 541, 545
I
IgG ........................................... 4, 5, 7, 10–12, 14–16, 21,
24–27, 77, 189, 200, 201, 335, 344, 345, 419,
424, 440, 471, 478, 485, 501, 537–546, 561,
564, 565, 570
Immunizations ....................................... 3, 64–66, 68, 69,
74–78, 250, 256, 261, 332, 339, 341, 342, 349,
352, 399, 400, 402, 407, 415, 424, 426, 428,
432, 434, 438–440, 448, 470, 472, 473, 478,
485, 513, 514, 519, 521, 523, 550, 556, 558
Immunogenicity ........................................... 3, 45, 46, 78,
253–255, 259, 267, 305, 357–365, 391,
406–408, 412, 419, 490, 491, 495, 525, 538, 560
Immunoglobulin .......................................... 4, 20, 21, 43,
313, 410, 537, 538
Immunoglobulin capture assay (ICA) .............. 10, 12–17
Immunogold labeling ................500, 501, 503, 508, 510
Immunoinformatics ..................................................44, 45
Inactivation.............................................2, 219, 252, 253,
255, 259, 260, 268, 331, 332, 346, 358, 466, 467
Injections ................................... 4, 65, 77, 274, 285–287,
290, 293, 295, 296, 325, 341, 342, 344, 349,
351, 352, 407–409, 414, 415, 428, 432, 437,
438, 440, 442, 444, 445, 455, 459, 470, 485,
514, 515, 521, 523, 551, 556, 558, 563, 568, 570
In silico vaccine discovery............................................... 29
Interferon-γ ....................................................................... 6
In vivo CTL................................................................... 551
In vitro vaccine production .......................................... 313
Irradiation.........................................................2, 351, 510
K
Killing assays .................................................................. 561
L
Lactic acid bacteria (LAB) ................................... 447–459
Lactococcus lactis................................................... 447–449
Laser force cytology (LFC) ................................. 575–585
Lipid-based vaccine carriers ........................ 392, 393, 396
Lipofection ........................................................... 391, 397
Liposomes........................................................5, 254, 478,
481–486, 514
Live attenuated strains .................................................. 331
Lyophilization ................................................93, 493–495
M
Machine learning (ML) ............................ 30, 33, 45, 576
Mammalian cells..................................... 83–94, 335, 344,
368, 369, 571
Membrane chromatography ......................................... 221
Microinjections.............................................................. 437
microRNA ............................................................ 334, 343
588
VACCINE DELIVERY TECHNOLOGY: METHODS AND PROTOCOLS
Index
227, 228, 233–239
Dry powder .......................................................... 489–497
E
Electroporation ............................... 67, 70, 71, 208, 209,
406, 407, 412, 414, 415, 440, 448
Elementary bodies (EBs) ..........................................19–27
ELISpot ......................................410, 411, 415, 419, 420
Encapsulation ..................5, 78, 440, 478, 484, 486, 507
Enzymatic synthesis ............................................. 313–328
Enzyme-linked immunosorbent assay
(ELISA)..........................77, 87, 89, 90, 132, 223,
242, 345, 399, 402, 409, 414–416, 428, 470,
471, 485, 486, 525, 526, 537–546
Enzyme-linked immunosorbent spot
(ELISpot).................................................. 525–535
Escherichia coli (E.coli) ......................................47, 53, 83,
106, 107, 186, 193, 194, 206, 208, 209, 268,
337, 346, 394, 425, 429, 462, 466, 467, 473,
474, 479, 480, 486
Eukaryotic expression vector........................................ 183
Eukaryotic pathogens ...............................................29–41
F
Flavivirus..............................................183, 184, 405–421
Flow cytometry ....................................16, 229, 230, 236,
237, 376, 382, 398, 515, 518–520, 523, 550,
551, 558, 561, 563, 565, 570
G
Gene delivery................................................................. 357
Gene inactivation .......................................................... 331
Gene therapy .............................................. 217, 367–371,
382, 526
Gene vector ................................................................... 357
Glycoconjugates .................................................. 2, 3, 6, 7,
205–214, 267, 287, 290–300, 307–309, 311,
314, 315
Glycoconjugate vaccines ............................ 267, 305–311,
313–328
Glycoconjugation .......................................................... 478
H
Hepatitis B virus (HBV) .................................. 83–93, 437
High performance liquid chromatography
(HPLC)...................................274, 291–296, 302,
316–318, 321, 325, 327
High-throughput process development (HTPD)119–133
Human mesenchymal stem cell
(hMSC) ..................................................... 380–382
Humoral responses .............................514, 538, 541, 545
I
IgG ........................................... 4, 5, 7, 10–12, 14–16, 21,
24–27, 77, 189, 200, 201, 335, 344, 345, 419,
424, 440, 471, 478, 485, 501, 537–546, 561,
564, 565, 570
Immunizations ....................................... 3, 64–66, 68, 69,
74–78, 250, 256, 261, 332, 339, 341, 342, 349,
352, 399, 400, 402, 407, 415, 424, 426, 428,
432, 434, 438–440, 448, 470, 472, 473, 478,
485, 513, 514, 519, 521, 523, 550, 556, 558
Immunogenicity ........................................... 3, 45, 46, 78,
253–255, 259, 267, 305, 357–365, 391,
406–408, 412, 419, 490, 491, 495, 525, 538, 560
Immunoglobulin .......................................... 4, 20, 21, 43,
313, 410, 537, 538
Immunoglobulin capture assay (ICA) .............. 10, 12–17
Immunogold labeling ................500, 501, 503, 508, 510
Immunoinformatics ..................................................44, 45
Inactivation.............................................2, 219, 252, 253,
255, 259, 260, 268, 331, 332, 346, 358, 466, 467
Injections ................................... 4, 65, 77, 274, 285–287,
290, 293, 295, 296, 325, 341, 342, 344, 349,
351, 352, 407–409, 414, 415, 428, 432, 437,
438, 440, 442, 444, 445, 455, 459, 470, 485,
514, 515, 521, 523, 551, 556, 558, 563, 568, 570
In silico vaccine discovery............................................... 29
Interferon-γ ....................................................................... 6
In vivo CTL................................................................... 551
In vitro vaccine production .......................................... 313
Irradiation.........................................................2, 351, 510
K
Killing assays .................................................................. 561
L
Lactic acid bacteria (LAB) ................................... 447–459
Lactococcus lactis................................................... 447–449
Laser force cytology (LFC) ................................. 575–585
Lipid-based vaccine carriers ........................ 392, 393, 396
Lipofection ........................................................... 391, 397
Liposomes........................................................5, 254, 478,
481–486, 514
Live attenuated strains .................................................. 331
Lyophilization ................................................93, 493–495
M
Machine learning (ML) ............................ 30, 33, 45, 576
Mammalian cells..................................... 83–94, 335, 344,
368, 369, 571
Membrane chromatography ......................................... 221
Microinjections.............................................................. 437
microRNA ............................................................ 334, 343
588
VACCINE DELIVERY TECHNOLOGY: METHODS AND PROTOCOLS
Index